|NASDAQ: DRRX||Healthcare / Drug Manufacturers / USA|
|4.46||-0.0700||-1.55%||Vol 8.58K||1Y Perf 614.62%|
|Mar 24th, 2023 11:10 DELAYED|
|- -%||- -|
|Target Price||34.67||Analyst Rating||Strong Buy 1.00|
|Potential %||684.39||Finscreener Ranking||★★★+ 51.04|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★+ 44.56|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★+ 41.06|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||19.82||Earnings Rating||Sell|
|Market Cap||109.20M||Earnings Date||3rd May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd May 2023|
|Estimated EPS Next Report||-0.50|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||69.19K|
|Avg. Monthly Volume||83.08K|
|Avg. Quarterly Volume||87.39K|
DURECT Corporation (NASDAQ: DRRX) stock closed at 4.53 per share at the end of the most recent trading day (a -1.09% change compared to the prior day closing price) with a volume of 67.48K shares and market capitalization of 109.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 95 people. DURECT Corporation CEO is James E. Brown.
The one-year performance of DURECT Corporation stock is 614.62%, while year-to-date (YTD) performance is 30.92%. DRRX stock has a five-year performance of 102.23%. Its 52-week range is between 3.165 and 9.70001, which gives DRRX stock a 52-week price range ratio of 19.82%
DURECT Corporation currently has a PE ratio of -4.00, a price-to-book (PB) ratio of 3.68, a price-to-sale (PS) ratio of 8.49, a price to cashflow ratio of 288.60, a PEG ratio of 2.32, a ROA of -42.09%, a ROC of -40.96% and a ROE of -71.55%. The company’s profit margin is -2.29%, its EBITDA margin is -125.90%, and its revenue ttm is $15.97 Million , which makes it $0.70 revenue per share.
Of the last four earnings reports from DURECT Corporation, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. DURECT Corporation’s next earnings report date is 03rd May 2023.
The consensus rating of Wall Street analysts for DURECT Corporation is Strong Buy (1), with a target price of $34.67, which is +684.39% compared to the current price. The earnings rating for DURECT Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DURECT Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DURECT Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.16, ATR14 : 0.32, CCI20 : -120.17, Chaikin Money Flow : -0.67, MACD : -0.19, Money Flow Index : 22.43, ROC : -4.63, RSI : 35.30, STOCH (14,3) : 11.29, STOCH RSI : 0.00, UO : 19.60, Williams %R : -88.71), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DURECT Corporation in the last 12-months were: Gail J. Maderis (Buy at a value of $117 142), Gail M. Farfel (Buy at a value of $31 546), Judith J. Robertson (Buy at a value of $102 391), Mohammad Azab (Buy at a value of $18 013)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, Remoxy, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States.
CEO: James E. Brown
Telephone: +1 408 777-1417
Address: 10260 Bubb Road, Cupertino 95014, CA, US
Number of employees: 95
Mon, 13 Mar 2023 20:30 GMT Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Intellia Therapeutics (NTLA)- TipRanks. All rights reserved.
Wed, 08 Mar 2023 13:40 GMT Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Alaunos Therapeutics (TCRT) and Marinus (MRNS)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.